The U.S. Food and Drug Administration is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne muscular dystrophy. The death occurred on June 7, 2025. The FDA has requested and received voluntary suspension of product distribution as it investigates the safety concerns. Elevidys is an adeno-associated virus vector-based gene therapy using Sarepta Therapeutics, Inc.’s AAVrh74 Platform Technology for the treatment of Duchenne muscular dystrophy. The product is administered as a single intravenous dose. Duchenne muscular dystrophy is a rare genetic condition characterized by progressive muscular weakness. The disease occurs due to a defective gene.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Arrowhead earns $100M milestone payment from Sarepta
- Sell Rating Reiterated for Sarepta Therapeutics Amid Regulatory Setbacks and Safety Concerns
- Hold Rating on Sarepta Therapeutics Amid CHMP Opinion and Financial Risks
- Cautious Hold Rating on Sarepta Therapeutics Amid Regulatory and Safety Concerns for Elevidys
- Sarepta downgraded to Underweight from Equal Weight at Barclays